Pharmaceutical Contract Manufacturing: World Industry and Market Outlook 2015-2025
LONDON, March 11, 2015 /PRNewswire/ --
Report Details
Contracted drug production - discover trends and segments with highest revenue potential
Where's outsourced pharma manufacturing heading? Visiongain's updated study predicts that industry's revenues from 2015. There you find potentials for sales growth, also understanding trends, technologies for drugs, clients' needs and opportunities.
That new report gives you revenue forecasts to 2025 at overall world market, submarket and national level. Avoid falling behind in data. Instead discover what's happening for those medical contracting services - outsourcing and off-shoring - hearing how you can gain.
Read on, then, to explore that industry and discover what revenue its future market could generate.
Forecasts from 2015-2025 and other analysis show you commercial prospects
From 2015, pharma contract manufacturing organisations (CMOs) hold great potential in medical materials, small-molecule drugs and biologicals. See how, where and why.
Besides revenue forecasting to 2025, our new study shows you historical data, growth rates and market shares. See developments in technology and service offerings, finding their meaning. And get 77 tables, 57 charts and two research interviews with companies.
There you hear what's happening in the industry for contract manufacturing organisations (CMOs). You see, from 2015, where needs and money exist. Discover the most lucrative pharmaceutical production services, including active compounds and complex agents.
Gains through understanding those outsourcing services - advantages for your work
Avoid struggles to find that business data. Now you can stay ahead in knowledge for contracted drug making, benefiting your research, analysis and decisions. Finding information you need for producing medicines just got quicker and easier.
And the following sections explain how you benefit from our new investigation.
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
Outsourced drug producing - forecasts from 2015 for the world market and submarkets
What are the secrets of that industry's progress? See expected trends there. Along with prediction of the overall world market for out-contracting drug production, our report shows you revenue forecasting of 11 submarkets to 2025 at world level:
• Active pharmaceutical ingredients (APIs), with sub forecasts for generic APIs, high potency active pharma ingredients (HPAPIs) and other products
• Finished dosage formulations (FDFs), with sub forecasts for solid dose forms, injectable dosages, and other agents
• Other applications of outsourced production - other services
• Clinical manufacturing
• Commercial manufacturing
Hear what's possible. Our analyses and discussions show you commercial potentials for manufacturing service providers and their technologies. Discover those money-gaining opportunities, finding how your company can prosper.
Use those predictions to expand your business and give you more influence. You get the forecasting leaders need, benefiting your authority. Our study helps you stay ahead.
You get geographical revenue predictions, too, seeing where to find the best prospects.
National and regional markets - what outlooks for demand, service provision and sales?
In developed and developing countries, opportunities for pharmaceutical CMOs will occur, often with rising potential. You see where and how.
Our analyses give individual revenue forecasts to 2025 for 12 national markets:
• United States (US)
• European Union - EU regional prediction
• Germany, France, the UK, Italy and Spain - EU5 countries
• Brazil, Russia, India, China - BRIC nations
• South Korea
• Japan
There explore progress and outlooks. And assess that medical production sector's future - hear about developments and find their meaning.
That way you gain feel for the industry. Find opportunity and see what's likely to happen. Our work explains, exploring issues shaping the future.
Forces affecting pharma CMOs and clients
Our report shows you activities, developments and events affecting that industry and market from 2015, including these:
• Trends for investing in biopharma manufacturing
• US and EU regulations, as well as requirements in other countries
• Generic Drug User Fee Act and API producing
• Demand for formulation developing services
• GMP standards, quality by design (QbD) and virtual pharma companies
• Potential for microreactors in outsourced drug making
• Backwards integration for generics producers.
The analysis also discusses other influences, including these:
• Investment in HPAPI manufacturing facilities
• Complex-molecule production, esp. biologics (inc. biosimilars) and orphan medicines
• Demand for softgel formulations and the shift to continuous manufacturing
• Green technology in contract pharmaceuticals production
• Aseptic filling for biological drugs and small-molecule medicines
• Development of antibody-drug conjugates (ADCs) and other novel proteins
• Lyophilisation, spray drying, hot-melt extrusion and fill-finish services.
There explore political, economic, social and technological questions, assessing outlooks for business. You examine forces stimulating and restraining that healthcare services industry.
You also see regulatory developments. Discover what that industry's present and future hold, then, exploring issues for contract drug makers and clients.
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
Companies and overall 2019 market value - how high can sales go?
What's possible for that industry? Our analysis predicts the world market for contract pharma manufacturing will reach $79.24bn in 2019. It will rise from $54.54bn in 2013, with strong revenue expansion to 2025.
Our study also explains what service needs, technologies and outsourcing providers hold greatest commercial potential.
In particular, you explore activities, capabilities and results of these companies:
• Catalent Pharma Solutions
• Lonza
• Evonik Degussa
• Royal DSM
• Teva API.
You also find discussions of these firms, among others:
• Boehringer BioXcellence
• Vetter Pharma-Fertigung
• Patheon
• Famar
• Fareva.
There you analyse participants' financial results, market shares, activities and outlooks. Our study covers 150 organisations. You also gain two interviews with authorities, including visiongain's discussions with leaders in SAFC and Vetter Pharma International.
So discover what companies in that industry think, say and do, helping you stay ahead.
Research and analysis on the CMO industry and market - data found nowhere else
Our new investigation helps you in these seven main ways:
• Revenues to 2025 for outsourced medicine production at overall world level - explore prospects for drug making technologies, investments, sales and contracts
• Prospects of 11 submarkets - discover the revenue generating potentials of services custom pharma manufacturing organisations offer
• Forecasts to 2025 for 12 national markets in the Americas, Europe and Asia - investigate developed and developing countries for those selling opportunities
• Outlooks for established and rising CMOs - assess portfolios, results, deals and outlooks, also with 10 company profiles
• Needs of clients - explore production requirements of drug companies, assessing commercial opportunities in serving drug developers and marketers
• Analysis of what stimulates and restrains the contract drug production market - see developments and challenges, helping you compete and gain advantages
• Interviews with companies and other news - discover what that industry's participants think, say and do, helping you stay ahead.
That report, by in-house UK-based analysts, benefits your reputation for knowledge, helping you succeed.
Analyses found nowhere else, helping your research, assessments and planning
Pharmaceutical Contract Manufacturing: World Industry and Market Outlook 2015-2025 provides independent analysis. There you receive business intelligence found only in our work. With that study you're less likely to fall behind in data or miss opportunity.
There find where opportunity and money lie. Gain, too, in recognition for insight. Our report's purpose is to benefit your research, analysis and decisions, also saving you time and effort.
Predictions for outsourced manufacture of pharmaceuticals - explore that industry's future
Our new study is for everyone investigating production of small-molecule medicines and biological drugs. There find revenue forecasting to 2025, seeing trends, developments and industry opinion. Avoid missing out - instead please get that report here now.
To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44(0)20-7336-6100
Companies Listed In This Report
AbbVie
Actavis
Aegerion Pharmaceuticals
Aenova Group
Aesica Pharma
Agência Nacional de Vigilância Sanitária (ANVISA)
Alexion Pharmaceuticals
Almac Group
Althea Technologies
AMRI
Aneona Group
Asociación Española de Fabricantes de Productos de Química Fina (AFAQUIM)
Aspen Pharmacare
Associação Brasileira da Indústria Farmoquímica e de Insumos Farmacêuticos (ABIQUIFI)
Association of British Pharmaceutical Industry (ABPI)
AstraZeneca
Banner Pharmacaps
Barring Private Equity Asia
Bausch & Lomb
Bayer
Ben Venue Laboratories
Bend Research
Biogen Idec
BioIndustry Association (BIA)
Biotest
Blackstone Group
Boehringer Ingelheim
Boehringer Ingelheim BioXcellence
Bristol-Myers Squibb Company
Bushu Pharmaceuticals
Cambrex
Cambridge Major Laboratories
Carbogen Amcis
Catalent Pharma Solutions
Cedarburg Hauser
Cell Therapy Catapult
Celladon Corporation
Celldex
Celltrion
Cenexi
Central Drugs Standard Control Organization (CDSCO)
Chemisch-Pharmazeutisches Laboratorium Ravensburg
Chemtrix
China FDA (CFDA)
Cipla
Cook Pharmica
CTC Bio
Daito Pharmaceutical
Delpharm
Department of Health and Family Welfare
Development and Reform Commission (NDRC)
Dishman Pharmaceuticals
DPx Holdings B.V.
Dr. Reddy's Laboratories
Eisai
Eli Lilly
Esteve Quimica
European Commission
European Medicines Agency (EMA)
Euticals
Evonik Degussa
Famar
Fareva
Food and Drug Administration (US FDA)
FUJIFILM Diosynth Biotechnologies,
Gallus Biopharamceutical, LLC.
G-CON
GEA Pharma-Systems
Genentech
GlaxoSmithKline (GSK)
Granules India
Haupt Pharma
Hexal
Hospira
Hospira One2One
Immunogen
Immunomedics
Indian Drug Manufacturer's Association (IDMA)
Indian Pharmaceutical Alliance
Innovent Biologics
International Society of Pharmaceutical Engineering (IPSE)
Janssen
JK Pharmaceutical
Knowledge Transfer Network (KTN)
Korea Food and Drug Administration (KFDA)
Korea Pharmaceutical Manufacturer's Association (KPMA)
Lonza
Lupin
Marinopoulos Group
Matrix Laboratories
Medice
Medichem
Medicines and Healthcare Products Regulatory Agency (MHRA)
Medicines Manufacturing Industry Partnership (MMIP)
Merck & Co.
Micron Technologies
Millenium
Ministry of Health (MOH)
Ministry of Health, Labor and Welfare (MHLW)
Ministry of Industry and Information Technology (MIIT)
Mitsui & Co.
Mylan
NPS Pharmaceuticals
Nycomed
Orchid Chemicals & Pharmaceuticals
Oxford Biomedica
Patheon
Pfizer
Pharmaceutical and Medical Devices Agency (PMDA)
Pharmacyclics
Piramal Pharma Solutions
Progenics
Quintiles
Recepta Biopharma
Recipharm
Redwood Bioscience
Rentschler Biotechnologie
Roche
ROVI
Royal DSM
SAFC
SafeBridge
Samsung BioLogics
Sandoz
Sanofi
Seattle Genetics
SELLAS Life Sciences Group
Shandong Xinhua
ShangPharma
Shire
Siegfried
Sigmar Italia
Sinochem
SMS Pharmaceuticals
Stada
Stem CentRx
Stevenage Bioscience Catalyst
Takeda
Teva API
Thermo Fisher Scientific
UMN Pharma
UNIGEN
Valeant Pharmaceuticals
Valerion Therapeutics, LLC.
Vetter Pharma-Fertigung GmbH
Vivante GMP Solutions
West Pharmaceutical Services
World Health Organization (WHO)
WuXi PharmaTech
Zhangjiang Biotech & Pharmaceutical Base Company
Zhejiang Jiang Yuan Tang Biotechnology
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com or call Tel: +44(0)20-7336-6100.
Share this article